Physician profile
Stella Bard
NPI 1457561862
$4,926.85
in general payments reported to CMS, 2019-2025
21 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,386 · 2020: $483 · 2021: $90.07 · 2022: $29.76 · 2023: $131 · 2024: $1,420 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Consulting Fee: $600 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.60 |
| Consulting Fee | $600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,162.35 | 2019-2025 | Rinvoq |
| Samsung Bioepis Co., Ltd. | $600.00 | 2024 | |
| Ucb, INC. | $496.29 | 2019-2025 | Bimzelx |
| Pfizer INC. | $472.02 | 2019-2022 | |
| Glaxosmithkline, LLC. | $386.89 | 2019-2024 | Benlysta |
| Novartis Pharmaceuticals Corporation | $321.69 | 2019-2025 | |
| Abbott Laboratories | $283.12 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $215.94 | 2019 | |
| Janssen Biotech, INC. | $167.57 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $136.59 | 2019 | |
| Amgen INC. | $130.83 | 2019-2021 | |
| Journey Medical Corporation | $124.85 | 2019 | |
| Incyte Corporation | $107.24 | 2024 | Opzelura |
| Almirall LLC | $105.81 | 2019 | |
| Celgene Corporation | $44.75 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.25 | 2019 | |
| Horizon Therapeutics Plc | $43.81 | 2020 | |
| Mallinckrodt Enterprises LLC | $30.95 | 2019 | |
| Fresenius Kabi USA, LLC | $25.87 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.03 | 2019 | |
| Radius Health, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Bard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.